PRA Health Sciences Inc (PRAH) EPS Estimated At $0.81

October 13, 2017 - By Richard Conner

 PRA Health Sciences Inc (PRAH) EPS Estimated At $0.81

Wall Street await PRA Health Sciences Inc (NASDAQ:PRAH) to release earnings on November, 1. Analysts forecast EPS of $0.81, up exactly $0.19 or 30.65 % from 2014’s $0.62 EPS. The expected PRAH’s profit could reach $50.71 million giving the stock 25.34 P/E in the case that $0.81 earnings per share is reported. After posting $0.62 EPS for the previous quarter, PRA Health Sciences Inc’s analysts now forecast 30.65 % EPS growth. The stock increased 0.82% or $0.67 during the last trading session, reaching $82.11. About 338,886 shares traded. PRA Health Sciences Inc (NASDAQ:PRAH) has risen 52.22% since October 13, 2016 and is uptrending. It has outperformed by 35.52% the S&P500.

PRA Health Sciences Inc (NASDAQ:PRAH) Ratings Coverage

Among 12 analysts covering PRA Health Sciences (NASDAQ:PRAH), 8 have Buy rating, 0 Sell and 4 Hold. Therefore 67% are positive. PRA Health Sciences had 23 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of PRA Health Sciences Inc (NASDAQ:PRAH) has “Outperform” rating given on Tuesday, August 8 by Robert W. Baird. The company was maintained on Thursday, June 1 by Jefferies. As per Friday, August 14, the company rating was reinitiated by Credit Suisse. The stock of PRA Health Sciences Inc (NASDAQ:PRAH) has “Mkt Perform” rating given on Monday, February 27 by Avondale. The stock of PRA Health Sciences Inc (NASDAQ:PRAH) earned “Neutral” rating by SunTrust on Thursday, November 19. UBS downgraded the shares of PRAH in report on Tuesday, September 6 to “Neutral” rating. The stock of PRA Health Sciences Inc (NASDAQ:PRAH) earned “Neutral” rating by Credit Suisse on Tuesday, June 21. The firm has “Outperform” rating by Credit Suisse given on Monday, February 6. Robert W. Baird maintained the stock with “Buy” rating in Monday, October 9 report. The firm earned “Buy” rating on Monday, September 11 by Jefferies.

PRA Health Sciences, Inc. is a contract research organization. The company has market cap of $5.14 billion. The Firm provides outsourced clinical development services to the biotechnology and pharmaceutical industries. It has a 53.38 P/E ratio. The Firm offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

More notable recent PRA Health Sciences Inc (NASDAQ:PRAH) news were published by: Globenewswire.com which released: “PRA Health Sciences, Inc. Reports Second Quarter 2017 Results and Updates Full …” on August 07, 2017, also Seekingalpha.com with their article: “PRA Health Sciences’ (PRAH) CEO Colin Shannon on Q2 2017 Results – Earnings …” published on August 12, 2017, Globenewswire.com published: “PRA Health Sciences to acquire Symphony Health Solutions, a leading provider …” on August 07, 2017. More interesting news about PRA Health Sciences Inc (NASDAQ:PRAH) were released by: Globenewswire.com and their article: “PRA Health Sciences Named Clinical Research Company of the Year” published on May 02, 2017 as well as Seekingalpha.com‘s news article titled: “PRA Health Sciences’ (PRAH) CEO Colin Shannon on Q1 2017 Results – Earnings …” with publication date: April 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.